A Randomised, Placebo-controlled, Double-blind (Double-dummy Technique),Crossover, Multi-centre Study, to Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler 9 microg, Compared With Serevent Diskus 50 microg. [Ensayo multicéntrico de distribución aleatoria, doble ciego (con doble enmascaramiento), cruzado y controlado con placebo para evaluar el comienzo del efecto del formoterol Turbuhaler 9 mcg comparado con salmeterol Accuhaler 50 mcg en pacientes con enfermedad pulmonar obstructiva crónica (EPOC)].

Trial Profile

A Randomised, Placebo-controlled, Double-blind (Double-dummy Technique),Crossover, Multi-centre Study, to Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler 9 microg, Compared With Serevent Diskus 50 microg. [Ensayo multicéntrico de distribución aleatoria, doble ciego (con doble enmascaramiento), cruzado y controlado con placebo para evaluar el comienzo del efecto del formoterol Turbuhaler 9 mcg comparado con salmeterol Accuhaler 50 mcg en pacientes con enfermedad pulmonar obstructiva crónica (EPOC)].

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2012

At a glance

  • Drugs Formoterol (Primary) ; Salmeterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Mar 2012 Results published in Clinical Drug Investigation.
    • 02 Dec 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 02 Dec 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top